Ramipril

also known as Altace · Tritace · Triatec · Altace (Ramipril) · Atlace · C09AA05 · Cardace · Corpril · +15 more

Small molecule targets ACE via inhibition

Developed for: hypertensive disorder · essential hypertension · proteinuria · type 2 diabetes mellitus · atherosclerosis · cardiovascular disorder · diabetic kidney disease · chronic kidney disease
+50 more
· glucose intolerance · peripheral arterial disease · systolic heart failure · atrial fibrillation · coronary artery disorder · COVID-19 · diabetes mellitus · IgA glomerulonephritis · myocardial infarction · symptomatic heart failure · Alport syndrome · Alzheimer disease · Becker muscular dystrophy · chemotherapy-induced toxicity · chronic renal failure syndrome · cognitive disorder · coronary microvascular disorder · diastolic heart failure · Duchenne muscular dystrophy · endomyocardial fibrosis · glomerulonephritis · heart disorder · hypertensive heart disease · hypertensive nephropathy · idiopathic spontaneous coronary artery dissection · intermittent vascular claudication · low density lipoprotein cholesterol, mild elevation of · metabolic syndrome X · mitral valve stenosis · myocardial ischemia · nephrosclerosis · oligospermia · pneumonia · rheumatic disease of mitral valve · rheumatic heart disease · rheumatoid arthritis · sickle cell disease · spermatogenic failure · stroke disorder · stutter disorder · systemic lupus erythematosus · acute coronary syndrome · acute myocardial infarction · disorder of defective peroxisome oxidative status · fibrotic liver disease · heart failure · migraine disorder · moderate heart failure · resistant hypertension · type 1 diabetes mellitus
Investigated by: Sanofi · Boehringer Ingelheim · Pfizer · Actavis Inc. · Ferrer Internacional S.A. · Gulhane School of Medicine
+111 more
· Assistance Publique - Hôpitaux de Paris · Aventis Pharmaceuticals · Canadian Institutes of Health Research (CIHR) · Dr. Reddy's Laboratories Limited · Gerstein, Hertzel, MD · Heart and Stroke Foundation of Ontario · Mario Negri Institute for Pharmacological Research · National Center for Cardiovascular Research Carlos III · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Northern California Institute of Research and Education · Teva Pharmaceuticals USA · University of Nebraska · Wake Forest University Health Sciences · Wyeth is now a wholly owned subsidiary of Pfizer · ARTTIC International Management Services · Aarhus University Hospital · Abant Izzet Baysal University · Agenzia Italiana del Farmaco · Ain Shams University · Astellas Pharma Canada, Inc. · Astellas Pharma Inc · Australian and New Zealand Intensive Care Research Centre · Baker Heart Research Institute · Baxter Healthcare Corporation · Bayer · Bayside Health · Berry Consultants · Bispebjerg Hospital · Brigham and Women's Hospital · Cadila Pharnmaceuticals · Cardiology Research UBC · Careggi University Hospital · Catholic University, Italy · Centre Hospitalier Universitaire de Besancon · Charite University, Berlin, Germany · Chinese University of Hong Kong · Duke University · European Commission · Evi Liliek Wulandari · Federación Argentina de Cardiología FAC · Fundacion Clinic per a la Recerca Biomédica · Gachon University Gil Medical Center · General University Hospital, Prague · German Federal Ministry of Education and Research · GlaxoSmithKline · Global Coalition for Adaptive Research · Göteborg University · HaEmek Medical Center, Israel · Heidelberg University · Hospital Authority, Hong Kong · Hospital Clínico Universitario de Valladolid · Hull University Teaching Hospitals NHS Trust · Indonesia University · Institute of Application-oriented Research and Clinical Trials GmbH · Instituto de Salud Carlos III · Intensive Care National Audit & Research Centre · Istituto Auxologico Italiano · Istituto Di Ricerche Farmacologiche Mario Negri · Karolinska Institutet · King Pharmaceuticals is now a wholly owned subsidiary of Pfizer · Kwame Nkrumah University Teaching Hospital · LivaNova · London School of Hygiene and Tropical Medicine · Martin Huelsmann · Medical Research Institute of New Zealand · Midas Pharma GmbH · Ministry of Health, France · Ministry of Health, Malaysia · Montreal Clinical Research Institute · Nantes University Hospital · Nat Intensive Care Surveillance - MORU · National Cancer Institute (NCI) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · all 117 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	ALTACE	—	1995-08-22 – 2000-10-04	fda.gov ↗
Approved	US (FDA)	ALTACE	—	1991-01-28	fda.gov ↗

Trials 97 · started per year

today

US approved 1991

199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 114 trials · 3 met primary
Phase 1	NCT04262765	Feb → Mar 2019	—	Midas Pharma GmbH	Completed	No outcome recorded
Phase 1	NCT03414723	Jan → Mar 2018	diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT01284621	Jan → Mar 2011	—	Boehringer Ingelheim	Completed	Met primary
Phase 1	NCT02214966	Oct → Dec 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02215005	Jun → Sep 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00310778	Mar 2006 → Mar 2007	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 1	NCT01164774	Oct 2005	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT01164761	Sep 2005	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT00863915	Oct 2004	—	Actavis Inc.	Completed	No outcome recorded
Phase 1	NCT00946621	Oct → Nov 2004	hypertensive disorder	Sandoz	Completed	No outcome recorded
Phase 1	NCT00864448	Oct 2004	—	Actavis Inc.	Completed	No outcome recorded
Phase 1	NCT00864162	Sep → Oct 2004	—	Actavis Inc.	Completed	No outcome recorded
Phase 1	NCT00828321	Aug → Oct 2004	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00829452	Aug → Oct 2004	—	Teva Pharmaceuticals USA	Completed	Met primary

Phase 28 trials · 2 missed
Phase 2	NCT04366050	May 2020 → May 2021	COVID-19	University of California, San Diego	Completed	Missed primary
Phase 2	NCT03475186	Mar 2019 → Mar 2025	cognitive disorder, glioblastoma	Wake Forest University Health Sciences	Completed	Mixed
Phase 2	NCT03329599	Feb 2019 → Dec 2021	atherosclerosis	Northern California Institute of Research and Education	Completed	Missed primary
Phase 2	NCT01234922	Feb 2011 → Dec 2013	cancer of unknown primary site, hypertensive disorder	Wake Forest University Health Sciences	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01004705	Sep 2009 → Mar 2011	low density lipoprotein cholesterol, mild elevation of	Ferrer Internacional S.A.	Terminated	No outcome recorded
Phase 2	NCT00923156	May 2009 → Feb 2011	systolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00054938	Mar 2003 → Dec 2005	systemic lupus erythematosus	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 2	NCT00005928	Jun 2000 → Feb 2002	atherosclerosis, coronary artery disorder, vasculitis	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2/34 trials · 2 missed
Phase 2/3	NCT04582097	Dec 2018 → Mar 2019	—	Ain Shams University	Completed	No outcome recorded
Phase 2/3	NCT00582777	Nov 2007 → Dec 2008	hypertensive nephropathy	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	Missed primary
Phase 2/3	NCT00141778	Apr 2005 → Jul 2010	atrial fibrillation	Vanderbilt University	Completed	Missed primary
Phase 2/3	NCT00273533	Jun 2004 → Jul 2006	rheumatoid arthritis	University of Zurich	Completed	No outcome recorded
Phase 327 trials · 2 met primary · 4 missed
Phase 3	NCT05963568	Apr 2026 → Jan 2029 expected	stroke disorder	Northern California Institute of Research and Education	Recruiting	No outcome recorded
Phase 3	NCT04591210	Jan 2021 → Dec 2024	COVID-19, cardiovascular disorder	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT04173949	Mar 2020 → Dec 2025 overdue	stutter disorder	HaEmek Medical Center, Israel	Active not recruiting	No outcome recorded
Phase 3	NCT03991910	Jun 2019 → Aug 2024	endomyocardial fibrosis, mitral valve stenosis, rheumatic disease of mitral valve, rheumatic heart disease	Indonesia University	Unknown	No outcome recorded
Phase 3	NCT02596126	Jul 2016 → Oct 2021	myocardial infarction	National Center for Cardiovascular Research Carlos III	Completed	No outcome recorded
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	Mixed
Phase 3	NCT02236806	Jul 2015 → Jun 2022	breast cancer, chemotherapy-induced toxicity	Careggi University Hospital	Unknown	No outcome recorded
Phase 3	NCT01646437	Jun 2012 → Jun 2020	cardiovascular disorder	Population Health Research Institute	Completed	Mixed
Phase 3	NCT01485978	Mar 2012 → Sep 2018	chronic kidney disease	Institute of Application-oriented Research and Clinical Trials GmbH	Completed	No outcome recorded
Phase 3	NCT01321255	Jan 2012 → May 2014	myocardial infarction	National Center for Cardiovascular Research Carlos III	Completed	Met primary
Phase 3	NCT00933231	Aug 2009 → May 2015	—	Astellas Pharma Inc	Completed	Missed primary
Phase 3	NCT00985322	May 2009 → Apr 2016	hypertensive disorder	Mario Negri Institute for Pharmacological Research	Completed	Missed primary
Phase 3	NCT00736294	Jul 2008 → Mar 2015	atrial fibrillation, atrial flutter	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 3	NCT00738660	Feb 2007 → May 2008	diabetic kidney disease	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 3	NCT00389519	Oct 2006 → Nov 2007	hypertensive disorder	Pfizer	Terminated	Met primary
Phase 3	NCT00208221	Aug 2006 → Jun 2007	hypertensive disorder, proteinuria, type 2 diabetes mellitus	Montreal Clinical Research Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00355589	Jul 2006 → Mar 2007	essential hypertension	Pfizer	Completed	No outcome recorded
Phase 3	NCT00281593	Apr 2006 → Apr 2007	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00437463	Jul 2004 → Sep 2010	glomerulonephritis	Sanofi	Completed	No outcome recorded
Phase 3	NCT00268619	Jun 2004 → Jul 2005	myocardial ischemia	Sanofi	Completed	No outcome recorded
Phase 3	NCT00489229	Oct 2002 → Dec 2005	diabetes mellitus, glucose intolerance	Universiti Sains Malaysia	Completed	Missed primary
Phase 3	NCT01225445	Apr 2002 → Jun 2010	IgA glomerulonephritis, proteinuria	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 3	NCT00480805	Aug 2001 → Oct 2002	hypertensive disorder, type 2 diabetes mellitus	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00095654	Jul 2001 → Oct 2006	cardiovascular disorder, glucose intolerance	Gerstein, Hertzel, MD	Completed	Mixed
Phase 3	NCT00140647	Jul 2001 → Jul 2006	atherosclerosis, glucose intolerance	Gerstein, Hertzel, MD	Completed	Missed primary
Phase 3	NCT00221845	Jan 1998 → Jul 2007	chronic renal failure syndrome, congenital anomaly of kidney and urinary tract, hypertensive disorder, impaired renal function disease	Heidelberg University	Completed	No outcome recorded
Phase 3	NCT04364139	Feb 1995 → Sep 2001	chronic kidney disease, nephrosclerosis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	Mixed

Phase 438 trials · 3 met primary · 4 missed
Phase 4	NCT07259512	Jun → Dec 2025 overdue	chronic kidney disease, systolic heart failure	Evi Liliek Wulandari	Recruiting	No outcome recorded
Phase 4	NCT05637853	Oct 2022 → Aug 2024 overdue	symptomatic heart failure	Göteborg University	Active not recruiting	No outcome recorded
Phase 4	NCT03201185	Feb 2018 → Aug 2021	—	Hospital Clínico Universitario de Valladolid	Unknown	Missed primary
Phase 4	NCT02842424	Feb 2016 → Jun 2026 overdue	peripheral arterial disease	University of Nebraska	Recruiting	No outcome recorded
Phase 4	NCT02817360	Feb 2016 → Dec 2025 overdue	heart disorder, type 2 diabetes mellitus	Martin Huelsmann	Recruiting	No outcome recorded
Phase 4	NCT02499822	Oct 2015 → Jul 2020	essential hypertension	Istituto Auxologico Italiano	Completed	No outcome recorded
Phase 4	NCT02525081	Jul 2015 → Jul 2016	coronary microvascular disorder	Bispebjerg Hospital	Completed	Missed primary
Phase 4	NCT01669434	Jun 2015 → Nov 2016	—	University of Nebraska	Completed	Met primary
Phase 4	NCT02008786	Jun 2014 → Sep 2019	idiopathic spontaneous coronary artery dissection	Cardiology Research UBC	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01500590	Nov 2011 → Aug 2018	hypertensive disorder, type 2 diabetes mellitus	Hospital Authority, Hong Kong	Unknown	No outcome recorded
Phase 4	NCT02901977	Mar 2011 → Feb 2015	hypertensive disorder	Karolinska Institutet	Completed	No outcome recorded
Phase 4	NCT01180413	Dec 2010 → Apr 2012	essential hypertension	Aarhus University Hospital	Completed	No outcome recorded
Phase 4	NCT01037530	Dec 2010 → Dec 2012	intermittent vascular claudication	Hull University Teaching Hospitals NHS Trust	Completed	No outcome recorded
Phase 4	NCT00980785	Apr 2009 → Jul 2011	Alzheimer disease, essential hypertension	University of Wisconsin, Madison	Completed	Missed primary
Phase 4	NCT00841880	Jan → Sep 2009	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00819845	Dec 2008 → Jun 2009	Becker muscular dystrophy, Duchenne muscular dystrophy	Catholic University, Italy	Unknown	No outcome recorded
Phase 4	NCT03099213	Nov 2008 → Apr 2010	coronary artery disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00542269	Mar 2008 → Jul 2009	metabolic syndrome X	Novartis	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01703234	Jan 2008 → Mar 2009	diabetic kidney disease, proteinuria	Gulhane School of Medicine	Completed	No outcome recorded
Phase 4	NCT00681226	Jan 2008 → Aug 2011	peripheral arterial disease	Bayside Health	Completed	Met primary
Phase 4	NCT00893425	Jan 2008 → Mar 2009	diabetic kidney disease, proteinuria	Gulhane School of Medicine	Completed	No outcome recorded
Phase 4	NCT00512759	Dec 2007 → Aug 2018	symptomatic heart failure	University Hospital, Basel, Switzerland	Completed	Missed primary
Phase 4	NCT00517322	Aug 2007 → Aug 2010	hypertensive heart disease	University of Insubria	Unknown	No outcome recorded
Phase 4	NCT00507845	Jun 2007 → Apr 2008	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00366119	Jun 2006 → Jun 2007	essential hypertension	Pacific Pharmaceuticals	Unknown	No outcome recorded
Phase 4	NCT00674596	Jan 2006 → Mar 2008	proteinuria, type 2 diabetes mellitus	Gulhane School of Medicine	Completed	No outcome recorded
Phase 4	NCT00535925	Oct 2005 → Dec 2011	diabetic kidney disease	University of Campania Luigi Vanvitelli	Completed	No outcome recorded
Phase 4	NCT00200694	Mar 2005 → Mar 2007	proteinuria	Nantes University Hospital	Terminated	No outcome recorded
Phase 4	NCT01053910	Oct 2003 → Jul 2005	atherosclerosis	Sanofi	Completed	No outcome recorded
Phase 4	NCT00356395	Aug 2003 → Mar 2006	hypertensive disorder	Gachon University Gil Medical Center	Completed	No outcome recorded
Phase 4	NCT00240422	Feb 2003 → Jul 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274599	Oct 2002 → Nov 2003	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274612	Oct 2002 → Nov 2003	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00044265	Jul 2002 → Nov 2004	hypertensive disorder	Pfizer	Completed	No outcome recorded
Phase 4	NCT00153101	Nov 2001 → Jun 2008	cardiovascular disorder	Boehringer Ingelheim	Completed	Mixed
Phase 4	NCT00325806	May 2000 → Aug 2005	hypertensive disorder	Sanofi	Completed	Met primary
Phase 4	NCT01115426	Jan 1997 → Jan 2007	IgA glomerulonephritis	University Magna Graecia	Completed	No outcome recorded
Phase 4	NCT00168467	—	peripheral arterial disease	Baker Heart Research Institute	Completed	No outcome recorded

Phase not applicable6 trials · 1 missed
—	NCT07099677	Aug 2025 → Jun 2026 overdue	essential hypertension	Abant Izzet Baysal University	Recruiting	No outcome recorded
—	NCT05133050	Jan 2022 → Dec 2024 overdue	Alport syndrome	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Not yet recruiting	No outcome recorded
—	NCT01856361	Jul 2013 → Jun 2016	oligospermia, spermatogenic failure	Weill Medical College of Cornell University	Terminated	No outcome recorded Stop: Enrollment
—	NCT01867047	Jun 2013 → Jun 2016	hypotensive disorder	Duke University	Terminated	Missed primary
—	NCT01504828	Jul 2012 → Dec 2015	diastolic heart failure, systolic heart failure	Newcastle-upon-Tyne Hospitals NHS Trust	Completed	No outcome recorded
—	NCT01195818	Sep 2010 → Sep 2014	sickle cell disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Comparator or background therapy73 trials
Phase 0	NCT02029118 Background	Oct 2012 → May 2015	—	Chengdu University of Traditional Chinese Medicine	Completed	Met primary
Phase 0	NCT00574834 Comparator	Mar 2007 → Aug 2014	metabolic syndrome X	University of Maryland, Baltimore	Terminated	No outcome recorded Stop: Business
Phase 1	NCT06304896 Comparator	May 2024 → May 2025	chemotherapy-induced toxicity	Arab Contractors Medical Centre	Unknown	No outcome recorded
Phase 1	NCT02907021 Background	Nov 2016 → Apr 2018	breast cancer, heart failure	Population Health Research Institute	Completed	No outcome recorded
Phase 1	NCT01432106 Comparator	Feb 2011 → Dec 2012	hypertensive disorder, metabolic syndrome X	University of Michigan	Withdrawn	No outcome recorded
Phase 1	NCT00946465 Comparator	Oct → Nov 2004	hypertensive disorder	Sandoz	Completed	No outcome recorded
Phase 1	NCT00829530 Comparator	Aug → Oct 2004	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 2	NCT04320589 Comparator	Jun 2019 → Aug 2021	pheochromocytoma	National Cancer Institute, Egypt	Completed	No outcome recorded
Phase 2	NCT03715998 Comparator	Jun 2019 → Jul 2021	myocardial infarction	Quantum Genomics SA	Completed	Missed primary
Phase 2	NCT04143412 Comparator	Feb 2019 → Feb 2020	diabetic kidney disease	Beni-Suef University	Unknown	No outcome recorded
Phase 2	NCT02632747 Background	May 2016 → Dec 2017	obesity disorder, type 1 diabetes mellitus, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT02791958 Comparator	Mar 2016 → Oct 2017	hypertensive disorder	Ferrer Internacional S.A.	Unknown	No outcome recorded
Phase 2	NCT01968759 Background	Oct 2013 → Oct 2015	chronic kidney disease	Mario Negri Institute for Pharmacological Research	Completed	Missed primary
Phase 2	NCT01302899 Background	Jan → Dec 2011	—	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT01362218 Comparator	Oct 2010 → Apr 2012	low density lipoprotein cholesterol, mild elevation of	Ferrer Internacional S.A.	Terminated	No outcome recorded
Phase 2	NCT01005290 Comparator	Oct 2009 → Oct 2010	hypertensive disorder	Ferrer Internacional S.A.	Terminated	No outcome recorded
Phase 2	NCT00939588 Comparator	Jul → Dec 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00732069 Comparator	Aug 2008 → Dec 2011	dialysis disequilibrium syndrome, end stage renal failure	Vanderbilt University	Completed	No outcome recorded
Phase 2	NCT00770497 Comparator	Mar 2007 → May 2008	hypertensive disorder	Takeda	Completed	No outcome recorded
Phase 2	NCT01402479 Comparator	Oct 2004 → Jul 2005	migraine disorder	Seoul National University Hospital	Completed	No outcome recorded
Phase 2/3	NCT07023016 Comparator	Nov 2023 → Feb 2025	chronic kidney disease, heart failure	National Heart Institute, Egypt	Completed	No outcome recorded
Phase 2/3	NCT03979976 Comparator	Mar 2011 → Aug 2013	systemic lupus erythematosus	Federal University of São Paulo	Completed	No outcome recorded
Phase 2/3	NCT01052272 Comparator	Jul 2005 → Nov 2010	diabetes mellitus	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 3	NCT05508035 Comparator	Jul 2023 → Mar 2027 expected	moderate heart failure	John Paul II Hospital, Krakow	Recruiting	No outcome recorded
Phase 3	NCT05849766 Comparator	Apr 2023 → May 2024	dilated cardiomyopathy	October 6 University	Completed	No outcome recorded
Phase 3	NCT03770936 Comparator	Oct 2018 → Oct 2026 expected	fibrotic liver disease	Tanta University	Recruiting	No outcome recorded
Phase 3	NCT02924727 Comparator	Dec 2016 → Feb 2021	acute myocardial infarction	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT01437371 Background	Aug 2011 → Jun 2014	heart failure	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 3	NCT01230034 Comparator	Oct 2010 → Jun 2011	hypertensive disorder, proteinuria, type 2 diabetes mellitus	University of Pavia	Unknown	No outcome recorded
Phase 3	NCT02729441 Comparator	Apr 2010 → Aug 2012	diabetes mellitus, proteinuria	Sunnybrook Health Sciences Centre	Completed	No outcome recorded
Phase 3	NCT00878969 Comparator	Jan 2010 → Jun 2015	disorder of defective peroxisome oxidative status	Vanderbilt University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00729365 Comparator	Jul 2008 → Jun 2010	type 1 diabetes mellitus	Northwestern University	Terminated	No outcome recorded
Phase 3	NCT00760214 Comparator	Jan 2008 → Apr 2009	hypertensive disorder	Takeda	Completed	Met primary
Phase 3	NCT00529451 Comparator	Sep 2007 → Jul 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00368277 Comparator	Sep 2006 → Feb 2008	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00679653 Comparator	Feb 2002 → Dec 2003	hypertensive disorder, obesity disorder	Abbott	Completed	No outcome recorded
Phase 4	NCT07547878 Comparator	Apr 2026 → Mar 2029 expected	chronic kidney disease, type 2 diabetes mellitus	Baylor Research Institute	Not yet recruiting	No outcome recorded
Phase 4	NCT07513883 Background	Mar 2026 → Sep 2028 expected	heart failure	Ziekenhuis Oost-Limburg	Recruiting	No outcome recorded
Phase 4	NCT06562582 Comparator	Jan 2025 → Dec 2027 expected	myocardial infarction	Vastra Gotaland Region	Recruiting	No outcome recorded
Phase 4	NCT06104423 Comparator	Oct 2023 → Feb 2024	hypertensive disorder	Menarini International Operations Luxembourg SA	Completed	No outcome recorded
Phase 4	NCT04662723 Background	May 2023 → Jun 2026 overdue	IgA glomerulonephritis	Schena Foundation	Recruiting	No outcome recorded
Phase 4	NCT05030818 Comparator	Oct 2022 → Mar 2026 overdue	coronary artery disorder	Fundación EPIC	Recruiting	No outcome recorded
Phase 4	NCT05122780 Background	Jul 2021 → Jul 2025 overdue	myocardial infarction	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Active not recruiting	No outcome recorded
Phase 4	NCT04330300 Comparator	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded Stop: Business
Phase 4	NCT02832973 Comparator	Sep 2015 → Dec 2017	resistant hypertension	Sao Jose do Rio Preto Medical School	Completed	No outcome recorded
Phase 4	NCT01922141 Comparator	May 2015 → Jun 2018	hypertensive disorder	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT02200822 Comparator	Jul 2014 → Feb 2019	heart failure	Hasselt University	Completed	No outcome recorded
Phase 4	NCT03011775 Background	Nov 2012 → Jun 2014	coronary atherosclerosis, metabolic syndrome X	Ukrainian Medical Stomatological Academy	Completed	No outcome recorded
Phase 4	NCT01743014 Comparator	Jul 2012 → Jul 2014	diabetic kidney disease, type 2 diabetes mellitus, vascular disorder	AHEPA University Hospital	Unknown	No outcome recorded
Phase 4	NCT01038895 Comparator	Nov 2009 → Mar 2010	hypertensive disorder, type 2 diabetes mellitus	University of Pavia	Unknown	No outcome recorded
Phase 4	NCT01042392 Comparator	Nov 2009 → Jan 2011	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00741585 Comparator	Sep 2008 → Jun 2018	chronic kidney disease, essential hypertension, stroke disorder	University of Vigo	Completed	No outcome recorded
Phase 4	NCT00772577 Comparator	Aug 2008 → Mar 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00657865 Comparator	Mar 2008 → Mar 2010	—	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00631917 Comparator	Feb 2008 → Sep 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00502242 Comparator	Dec 2007 → Sep 2013	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT00702936 Comparator	Nov 2007 → Aug 2008	acute coronary syndrome, coronary artery disorder, myocardial infarction	Catholic University of the Sacred Heart	Unknown	No outcome recorded
Phase 4	NCT00473174 Comparator	Mar 2007 → Dec 2008	essential hypertension	University of Vigo	Completed	No outcome recorded
Phase 4	NCT00391846 Background	Oct 2006 → Jan 2009	left ventricular failure	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00607672 Comparator	Aug 2006 → Aug 2011	coronary artery disorder	Vanderbilt University	Completed	No outcome recorded
Phase 4	NCT00608465 Comparator	May 2006 → May 2009	metabolic syndrome X	Vanderbilt University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00421863 Background	Feb 2005 → Jan 2009	hypertensive disorder	Heart Care Foundation	Completed	No outcome recorded
Phase 4	NCT00095290 Comparator	Sep 2004 → Nov 2005	proteinuria	Bristol-Myers Squibb	Completed	Missed primary
—	NCT07045038 Background	Jul 2025 → Apr 2026	moderate heart failure	Cairo University	Completed	No outcome recorded
—	NCT07184918 Comparator	Feb 2024 → Jun 2025	acute kidney injury	Tanta University	Completed	No outcome recorded
—	NCT07315139 Comparator	Feb → Aug 2023	chronic kidney disease	Ain Shams University	Completed	No outcome recorded
—	NCT02086019 Background	May 2014 → Sep 2019	acute coronary syndrome	Brighton and Sussex University Hospitals NHS Trust	Completed	No outcome recorded
—	NCT01686230 Background	Jul 2012 → Jul 2017	intermediate coronary syndrome	Chengdu University of Traditional Chinese Medicine	Completed	No outcome recorded
—	NCT01078363 Comparator	Jun 2009 → Apr 2015	—	Stanford University	Completed	No outcome recorded
—	NCT00443794 Comparator	Mar 2007 → Oct 2008	cardiovascular disorder	St. John's Research Institute	Completed	No outcome recorded
—	NCT00292162 Comparator	Jan 2007 → Jul 2009	atrial fibrillation, heart failure	NHS Greater Glasgow and Clyde	Completed	No outcome recorded
—	NCT00750308 Comparator	Dec 2006 → Jan 2009	metabolic syndrome X	Vanderbilt University	Completed	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 3

Date	Issuer	Release
2022-10-26	Ferrer Internacional S.A.	Results More than 350 Latin American doctors participate in the second Ferrer Summit in the region ferrer.com ↗ the results of SECURE reveal, for the first time, that the polypill containing aspirin, atorvastatin and ramipril achieves clinically relevant reductions in recurrent cardiovascular events in patients who have suffered a myocardial infarction.
2021-11-30	Ferrer Internacional S.A.	Results Lower risk of major cardiovascular events with the CNIC polypill compared to the administration of the monocomponents separately ferrer.com ↗
2021-07-09	Midas Pharma GmbH	Regulatory Value Added Medicines – A key for differentiation and success in the pharmaceutical world midas-pharma.com ↗ In cooperation with one of our development partners Midas was able to get approval for the first new fixed dose combination product including three active pharmaceutical ingredients (Ramipril+Amlodipine+HCTZ) within the EU.

All press releases naming this drug 3 releases

Date	Issuer	Release
2022-10-26	Ferrer Internacional S.A.	More than 350 Latin American doctors participate in the second Ferrer Summit in the region ferrer.com ↗
2021-11-30	Ferrer Internacional S.A.	Lower risk of major cardiovascular events with the CNIC polypill compared to the administration of the monocomponents separately ferrer.com ↗
2021-07-09	Midas Pharma GmbH	Value Added Medicines – A key for differentiation and success in the pharmaceutical world midas-pharma.com ↗

Evidence & citations 28 cited values

Every value below carries the sentence it was read from. 172 sources stand behind the page.

Field	Value	Cited text
Known as	Ramipril	“Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ 165 “In the second week, RAASi will be introduced with either angiotensin converting enzyme inhibitor (ACEi)(Ramipril or Enalapril) or angiotensin receptor neprilisyn inhibitor...” NCT05637853 ↗ “including the beta-blocker, carvedilol, and the ACE-I, ramipril, as tolerated, at the maximum doses tolerated, up to carvedilol 25mg BID and ramipril 10mg once daily” NCT02907021 ↗ “The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril.” NCT04591210 ↗ “A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol.” NCT05963568 ↗ “polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily” PMID 33186492 ↗ Nov 2020 “A capsule of Polycap contained aspirin 100 mg, simvastatin 20 mg, hydrochlorothiazide 12.5 mg, ramipril 5 mg, and atenolol 50 mg.” PMID 39082406 ↗ Jul 2024 “additional antihypertensive medication before bedtime [diltiazem 60-120 mg, hydralazine 25 mg, or additional ramipril 5 mg]” PMID 23172931 ↗ Nov 2012 “ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily” NCT01500590 ↗ “Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril” NCT04330300 ↗ “Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.” NCT01686230 ↗ Show 155 more sources
Known as	Altace	“Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ 7 “PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN” NCT00274599 ↗ “Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension” NCT00281593 ↗ “A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks” NCT02791958 ↗ “Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)” NCT00946621 ↗ “Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)” NCT00946465 ↗ NCT00829530 ↗ NCT07547878 ↗
Known as	Altace (Ramipril)	“Altace (Ramipril)” NCT01432106 ↗
Known as	Atlace	“commercially available reference product Atlace® manufactured by Monarch Pharmaceuticals Inc.” NCT00864448 ↗
Known as	C09AA05	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Cardace	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Corpril	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Delix	“Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.” NCT01485978 ↗
Known as	Ecator	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	HOE498	“RAMIPRIL HOE498” NCT03099213 ↗
Known as	Hopace	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Lopace	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	NSC-758933	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Pramace	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	RAM	“This is a Phase IV, interventional, multicenter, open-label, multinational study with 2 study periods (a Run-in period of 4 weeks and an Assessment period of 12 weeks) to...” NCT06104423 ↗
Known as	Ramace	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Ramipres	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Ramipril component of polycap	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Ramiprin	“The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension” NCT00366119 ↗
Known as	Ranace	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Triatec	“using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).” NCT00512759 ↗ 1 NCT00421863 ↗
Known as	Tritace	“The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension” NCT00366119 ↗ 4 “All patients will enroll to maximum doses guideline medical treatment that include (Beta blockers-Aspocid- Ator-Concor-Tritace).” NCT07045038 ↗ “25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day.” NCT04143412 ↗ “Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®” NCT05849766 ↗ “Tritace 2.5-10 mg/day” NCT04320589 ↗
Known as	Unipril	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Known as	Vesdil	ChEMBL registry synonym — accepted as the source's own label CHEMBL1168 ↗
Action	Inhibit	“Angiotensin converting enzyme (ACE) inhibitor therapy reduces cardiovascular events” NCT00005928 ↗
Modality	Small molecule	— CHEMBL1168 ↗
Route	Oral	“Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.” NCT00095290 ↗
Target	ACE	“angiotensin-converting enzyme (ACE) inhibitor ramipril” PMID 19477351 ↗ Jun 2009